Diversified revenue and earnings base with four strong business segments
Leading positions in non-cyclical markets with predictable growth
Industry-leading organic growth in all business segments
Strong earnings performance and cash flow generation
Attractive shareholder returns
Prudent financial management
"The first half of 2018 was a very good one for Fresenius. After our successful start, we have delivered a strong second quarter with continued healthy growth in sales and earnings. All four business segments contributed to this, and all four business segments display outstanding prospects for the future. For Fresenius Kabi, we are even a bit more optimistic than before. We are therefore fully on track to achieve our ambitious growth targets as we steer toward another excellent year for Fresenius."
(Stephan Sturm, Chairman of the Management Board)
Fresenius Kabi has opened a new state-of-the-art compounding center in Canada. It involves an investment of 11 million Canadian dollars (more than €7 million), and the new site expands the company’s presence in Mississauga, Ontario. Fresenius Kabi is responding to increasing demand for large batches of compounded medications for patients in Canadian hospitals, and the 35,000-square-foot (3,300-square-meter) compounding center has the capacity to expand. The new facility is expected to employ 70 people by 2022.
Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11455, a biosimilar candidate for Neulasta® (pegfilgrastim), has met its primary endpoints in the two pivotal clinical studies. For more information please see the website of Fresenius Kabi.
The price increase for hospital services in Germany has been set at 2.65% for 2019. This is in line with the level of past years.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, is opening a new hospital in Cordoba today. The company now has six hospitals in Andalusia, Spain’s most southernly autonomous community. The six-floor, approximately 25,000-square-meter (269,000-square-foot) facility includes 100 large private patient rooms, a 24-hour emergency department, seven operating rooms and a surgical outpatient clinic. Quirónsalud has invested €50 million in the new hospital.
Fresenius Helios has opened a new emergency unit at Helios Hospital Leisnig, in the eastern German state of Saxony. It contains four modern examination rooms and a specially equipped reanimation room, which will enable the hospital to provide even better care for its emergency patients, who now number some 10,000 annually. Architecturally optimized for medical processes and procedures, the new emergency unit was built in only 12 months. It required an investment by Fresenius Helios of about €1 million.
Atropine Sulfate Injection further expands the company's anesthesia and analgesia portfolio.
Glycopyrrolate Injection is the newest addition to the company’s anesthesia and analgesia portfolio.
Fresenius Helios will take responsibility for practical instruction as part of the first worldwide digitalized medical studies program. The new course of study meets European certification standards and will start in the winter semester 2018/2019 at the EDU College of Medicine, Malta. Theoretical components of a bachelor’s and follow-on master’s program will be available solely via an online platform. Students will be networked into learning communities taught by faculty. About one-third of the course is practical instruction that will take place in hospitals operated by Fresenius Helios in Germany. The program initially will be limited to 75 students. The long-term goal is up to 3,000 students.
Fresenius Kabi is expanding its production and warehouse capacity in Runcorn, England, to meet increasing demand in United Kingdom’s homecare market and from UK and Ireland hospitals. The expansion’s first stage will be a new distribution and operations center, scheduled to open in early 2019. A second services unit for producing aseptically compounded parenteral nutrition products will be completed by 2020. Fresenius Kabi will invest over €9 million in the expansion.
Jiménez Díaz Foundation University Hospital in Madrid has again been awarded the EFQM Recognized for Excellence award with the maximum five stars, this time also receiving the highest rating of any hospital in Spain. The 667-bed facility earned more than 650 points on the rating scale used by the European Foundation for Quality Management during a comprehensive management and process evaluation earlier this year. In the award presentation, the EFQM cited Jiménez Díaz Foundation University Hospital’s intensive focus on patient care, as well as its continuous improvements in treatments and the use of medical technology. This leading teaching hospital is part of the Quirónsalud group, the Spanish unit of Fresenius Helios.
Melphalan Hydrochloride for Injection is the newest addition to the company’s oncology portfolio.
Palonosetron Hydrochloride Injection is the newest addition to the company’s expanding portfolio of IV drugs. It is an antiemetic that can be used for chemotherapy-induced nausea and vomiting.
Quirónsalud Tenerife Hospital has opened a new intensive care unit, equipped with the latest medical equipment for treating as many as six critically ill patients at a time. Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, invested more than €1 million in the 400-square-meter (4,300-square-foot) ICU.
Fresenius Helios recently opened a 130-bed building at the company’s hospital in Dachau, a city near Munich. The new structure is part of a €55 million renovation and expansion program that will include a modernization of the existing hospital building over the next two years. Meanwhile, in the northern German city of Nienburg/Weser, work has started on a building that will almost double the size of the emergency department at Fresenius Hospital Mittelweser. About €2.3 million is being invested in this project, which is scheduled for completion in the autumn.
Fresenius Helios has presented the new Helios Science Prize for outstanding research by employees that contributes to improved treatment quality. The three winners all work at hospitals in Germany and were honored for their work in different areas of medicine. The prize, which comes with a cash award, went to Dr. Jitka Veldema of Helios Hospital Kipfenberg (for her work on stroke rehabilitation), Prof. Dr. Alexander Kreuter of Helios St. Elisabeth Hospital in Oberhausen (cancer diagnosis in HIV patients), and Dr. Patrick Weil of Helios University Hospital in Wuppertal (testicular cancer therapy).
Remifentanil is the newest addition to the company’s extensive portfolio of anesthesia and analgesia products. Remifentanil is a controlled substance sold only to licensed health care professionals for patient care and is distributed under strict controls in compliance with FDA and DEA regulations.
Standard & Poor’s has revised Fresenius’ corporate credit outlook to positive from stable in late December 2017. The corporate credit rating was affirmed. Hence, Fresenius is now rated BBB- with positive outlook by Standard & Poor’s. Fresenius is rated investment grade by all of the three leading rating agencies Standard & Poor’s, Moody's and Fitch.
VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2017” at the World Spa Awards. Three VAMED Vitality World facilities – St. Martins Thermal Spa & Lodge and Thermal Spa Laa Hotel & Spa, both in Austria, and Aquaworld Resort Budapest in the Hungarian capital – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria and Hungary.
Bortezomib for intravenous use is the first and only available alternative to Bortezomib for Injection and is the newest addition to the company’s expanding oncology portfolio.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, will build a hospital in the city of Alcalá de Henares, just outside of Madrid. The approximately 11,000-square-meter (118,000-square-foot) facility will include 106 beds, four operating rooms and two delivery rooms. Quirónsalud will invest about €27 million in the new hospital. It is scheduled to open in 2019.
Fresenius Kabi has submitted a Marketing Authorization Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. The application is the first biosimilar regulatory filing for Fresenius Kabi. Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.
Fresenius Kabi is expanding its activities in Indonesia. PT ETHICA Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceuticals company SOHO Global Health, opened a new plant in Cikarang, just outside the country’s capital and biggest city Jakarta. The plant’s approximately 230 employees will produce a wide range of injectable drugs needed in therapeutic areas including gynecology, anesthesia and intensive care. The products are planned for use by Indonesian patients and for export to other Southeast Asian countries. Fresenius Kabi employs a total of about 530 people in Indonesia.
Quarterly Financial Report Q2 2018 (IFRS) (PDF, 387 KB)
Fresenius Factsheet H1/2018 (PDF, 465 KB)
Quarterly Financial Report Q1 2018 (IFRS) (PDF, 334 KB)
Annual Report 2017 (IFRS) (PDF, 3.21 MB)
Quarterly Financial Report Q3 2017 (IFRS) (PDF, 350 KB)
Investor Relations General Presentation (PDF, 1.36 MB)
Quarterly Financial Report Q2 2017 (IFRS) (PDF, 380 KB)
Quarterly Financial Report Q1 2017 (IFRS) (PDF, 295 KB)
Annual Report 2016 (U.S. GAAP) (PDF, 2.89 MB)
Consolidated Financial Statements / Management Report 2016 (IFRS) (PDF, 1.02 MB)
Quarterly Financial Report Q3 2016 (US-GAAP) (PDF, 337 KB)
Quarterly Financial Report Q3 2016 (IFRS) (PDF, 373 KB)
Quarterly Financial Report Q2 2016 (US-GAAP) (PDF, 369 KB)
Quarterly Financial Report Q2 2016 (IFRS) (PDF, 333 KB)
Quarterly Financial Report Q1 2016 (US-GAAP) (PDF, 830 KB)
Quarterly Financial Report Q1 2016 (IFRS) (PDF, 309 KB)
Annual Report 2015 (US-GAAP) (PDF, 3.18 MB)
Consolidated Financial Statements / Management Report 2015 (IFRS) (PDF, 1.02 MB)
Quarterly Financial Report Q3 2015 (US-GAAP) (PDF, 327 KB)